11-羟基-5,11-二氢-二苯并[B,E]氮杂卓-6-酮 | 723-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 11-羟基-5,11-二氢-二苯并[B,E]氮杂卓-6-酮
• 英文名称: 11-hydroxy-6-oxo-5,11-dihydro-6H-dibenzazepine
• 英文别名: 11-hydroxy-5,11-dihydrodibenzo[b,e]azepin-6-one；11-hydroxy-5,11-dihydro-dibenzo[b,e]azepin-6-one；5,6-dihydro-11-hydroxy-11H-dibenz[b,c]azepin；11-Hydroxy-6-oxo-5,6-dihydro-11H-dibenzoazepin；11-Hydroxy-6-oxo-5,6-dihydro-morphanthridin；5,6-Dihydro-11-hydroxy-6-oxomorphanthridin；11-Hydroxy-5,11-dihydro-dibenzo[b,e]azepin-6-one；11-hydroxy-5,11-dihydrobenzo[c][1]benzazepin-6-one
• CAS: 723-87-5
• 化学式: C₁₄H₁₁NO₂
• 分子量: 225.247
• InChiKey: MVDLFUHQOPGQGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  11-羟基-5,11-二氢-二苯并[B,E]氮杂卓-6-酮 在 氯化亚砜 作用下， 生成 11-phenoxy-5,11-dihydrobenzo[c][1]benzazepin-6-one
  参考文献：
  名称：

  Alkoxy-11 dibenzo[b,e]azépinones-6 à activité anti-convulsivante

  摘要：

  DOI：

  10.1016/0223-5234(88)90145-6
• 作为产物：
  描述：

  5H-二苯并[b,e]氮杂卓-6,11-二酮 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 11-羟基-5,11-二氢-二苯并[B,E]氮杂卓-6-酮
  参考文献：
  名称：

  胍基-酰基胍生物立体异构方法在精氨酸酰胺型NPY Y2受体拮抗剂中的应用

  摘要：

  诸如胍基等强碱性基团是至关重要的结构元素，但它们会损害许多生物活性化合物的药物样，包括G蛋白偶联受体（GPCR）的配体。作为致力于寻找胍类生物等位基因的项目的一部分，合成了与BIIE0246相关的精氨酸酰胺型神经肽Y（NPY）Y 2受体（Y 2 R）拮抗剂。从鸟氨酸衍生物开始，N ģ -acylated argininamides通过胍基化量身定做的单-Boc保护的得到Ñ -acyl-小号-methylisothioureas。研究了这些化合物的Y 2 R拮抗作用（钙测定），Y 2R亲和力和NPY受体亚型选择性（流式细胞术结合测定）。大多数N G取代的（S）-精氨酰胺显示出与母体化合物相似的Y 2 R拮抗活性和结合亲和力，而带有末端胺的N G酰化或氨基甲酰化类似物则更为出色（Y 2 R：K i和K B值在低纳摩尔范围内）。这表明化合物的碱性虽然比胍的碱度低4-5个数量级，但足以与Y 2的酸性氨基酸形成关键相互作用R

  DOI：

  10.1002/cmdc.201100241

文献信息

• Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists
  作者：Gopi Kumar Mittapalli、Danielle Vellucci、Jun Yang、Marion Toussaint、Shaun P. Brothers、Claes Wahlestedt、Edward Roberts

  DOI：10.1016/j.bmcl.2012.04.107

  日期：2012.6

  Highly potent and selective small molecule neuropeptide Y Y2 receptor antagonists are reported. The systematic SAR exploration of a hit molecule N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]piperidine-1-carbothioamide, identified from HTS, led to the discovery of highly potent NPY Y2 antagonists 16 (CYM 9484) and 54 (CYM 9552) with IC50 values of 19 nM and 12 nM respectively.

  报告了高效和选择性的小分子神经肽 Y Y2 受体拮抗剂。从 HTS 鉴定的命中分子N- (4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]piperidine-1-carbothioamide的系统 SAR 探索导致发现了高效的 NPY Y2 拮抗剂16 (CYM 9484)和54 (CYM 9552)，IC 50值分别为 19 nM 和 12 nM。
• PHENYLPIPERIDINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0974583A1

  公开（公告）日：2000-01-26

  A phenylpiperidine derivative or pharmaceutical acceptable salt thereof represented by formula (I):    wherein X represents CH or N; Y-Z represents CH2-O, CH2-S, CH2-CH2, CH=CH or CONR5 (wherein R5 represents hydrogen or lower alkyl); R1 represents hydrogen, lower alkyl, halogen, lower alkoxy or trifluoromethyl; and R2, R3 and R4 are the same or different and each represents hydrogen, lower alkyl or QR6 (wherein Q represents a single bond or lower alkylene, and R6 represents hydroxy, lower alkoxyalkoxy, lower alkoxy, lower alkylthio, nitro, halogen, lower alkanoyloxy, lower alkoxycarbonyl, lower alkanoyl or carboxyl). The present invention provides novel phenylpiperidine derivatives useful as analgesics.

  由式(I)代表的苯基哌啶衍生物或其药物可接受盐： 其中 X 代表 CH 或 N；Y-Z 代表 CH2-O、 -S、 - 、CH=CH 或 CONR5（其中 R5 代表氢或低级烷基）；R1 代表氢、低级烷基、卤素、低级烷氧基或三氟甲基；R2、R3 和 R4 相同或不同，各自代表氢、低级烷基或 QR6（其中 Q 代表单键或低级亚烷基，R6 代表羟基、低级烷氧基、低级烷氧基、低级烷硫基、硝基、卤素、低级烷酰氧基、低级烷氧羰基、低级烷酰基或羧基）。 本发明提供了可用作镇痛剂的新型苯基哌啶衍生物。
• New triazine derivatives as potent modulators of multidrug resistance
  作者：Alain Dhainaut、Gilbert Regnier、Ghanem Atassi、Alain Pierre、Stephane Leonce、Laurence Kraus-Berthier、Jean Francois Prost

  DOI：10.1021/jm00091a017

  日期：1992.6

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.
• Irurre, J.; Marquillas, F.; Alvarez-Larena, A., Canadian Journal of Chemistry, 1994, vol. 72, # 2, p. 334 - 338
  作者：Irurre, J.、Marquillas, F.、Alvarez-Larena, A.、Piniella, J. F.

  DOI：——

  日期：——
• Irurre J., Marquillas F., Alvarez-Larena A., Piniella J. F., Can. J. Chem, 72 (1994) N 2, S 334- 338
  作者：Irurre J., Marquillas F., Alvarez-Larena A., Piniella J. F.

  DOI：——

  日期：——